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Abstract
Functional modeling of normal breast epithelial hierarchy and stromal-epithelial cell interactions 
have been difficult due to inability to obtain sufficient stem-progenitor-mature epithelial and 
stromal cells. Recently reported epithelial reprogramming assay has partially overcome this 
limitation, but cross contamination of cells from the feeder layer is a concern. The purpose of this 
study was to develop a feeder-layer independent inexpensive method to propagate multiple cell 
types from limited tissue resources. Cells obtained after enzymatic digestion of tissues collected at 
surgery or by core-needle biopsies were plated on tissue culture dishes pre-coated with laminin-5-
rich conditioned media from the rat bladder tumor cell line 804G and a defined growth media with 
inhibitors of ROCK, TGFβ, and BMP signaling. Cells were characterized by flow cytometry, 
mammosphere assay, 3D cultures, and xenograft studies. Cells from the healthy breasts included 
CD10+/EpCAM- basal/myoepithelial, CD49f+/EpCAM+ luminal progenitor, CD49f-/EpCAM+ 
mature luminal, CD73+/EpCAM+/CD90- rare endogenous pluripotent somatic stem, CD73+/
CD90+/EpCAM-, Estrogen Receptor alpha (ERα)-expressing ALCAM (CD166)+/EpCAM+, and 
ALDFLUOR+ stem/luminal progenitor subpopulations. Epithelial cells were luminal (KRT19+), 
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basal (KRT14+) or dual positive luminal/basal hybrid cells. While breast cells derived from 
BRCA1, BRCA2, and PALB2 mutation carriers did not display unique characteristics, cells from 
women with breast cancer protective alleles showed enhanced differentiation. Cells could also be 
propagated from primary tumors and metastasis of breast, ovarian, and pancreatic cancer-
neuroendocrine subtype. Xenograft studies confirmed tumorigenic properties of tumor-derived 
cells.
Keywords
Primary epithelial cells; TGFβ and BMP inhibition; breast cancer; luminal progenitor; culture 
condition
Introduction
The breast tissue is composed of the epithelial and stromal cells cushioned by layers of 
adipose cells (1). The ability to culture and propagate various type of cells that form the 
breast hierarchy, which include the stem-progenitor-mature epithelial cells and stromal cells 
is of vital importance for all functional studies related to in vitro characterization of different 
cell types, epithelial-stromal interaction, elucidation of molecular mechanisms of normal 
cell differentiation, cancer initiation, and progression. Several protocols have been 
developed that support the propagation of breast epithelial cells, which in large part are 
biased towards outgrowth of basal cells [summarized in (2)]. Several of these culture 
protocols utilize irradiated mouse embryonic fibroblast or human foreskin fibroblasts as 
feeder cells to maintain the pluripotent state of stem cells (3,4). Normal breast stromal cells 
have morphological features and characteristics of fibroblasts. It is also difficult to 
distinguish mesenchymal and adipose stem cells from fibroblasts without profiling for cell 
surface markers. Therefore, an ideal system should allow growth of as many cell types of a 
tissue as possible and should utilize alternatives to feeder layers such as extracellular matrix 
proteins and small molecules that enable the maintenance of adult stem cells and their 
lineage commitment properties. In this respect, vitamin C and inhibitors of Rho associated 
coil-coil containing protein kinase (ROCK) have been shown to be effective in stem cell 
reprogramming and in preventing matrix detachment-induced apoptosis of stem cells, 
respectively (3,5).
A recent study reported that plating adult epithelial cells from lungs on tissue culture dishes 
pre-coated with laminin-5-rich conditioned media from the rat bladder cancer cell line 804G 
and in media containing dual inhibitors of SMAD/BMP pathways permits propagation of 
diverse epithelial cells (6). We had previously shown that maintaining primary breast 
epithelia cells in low glucose containing media and limiting the use of DMSO as a solvent 
for small molecules enable long-term culture of breast epithelial cells from a core needle 
biopsy on a feeder layer and these cultured cells maintain stem-progenitor-differentiated cell 
hierarchy (7). The goals of this study were to determine whether combining these two 
methods would permit growth of multiple cell types of the breast without the need for feeder 
layer and whether the technique can be extended to other cancer types as well as biopsies 
from metastatic sites. Since there is growing evidence for heterogeneity between primary 
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tumor and metastasis within an individual patient, despite sharing large number of driver 
mutations (8), there is an urgent need to develop methods that enable characterization of 
metastatic cells in vitro for therapeutic decision making. We show that the method described 
here is effective in propagating primary epithelial cells that include but is not limited to 1) 
normal breast, 2) carriers of BRCA1, BRCA2, PALB2 mutations or breast cancer protective 
alleles, 3) primary breast cancer, 4) pleural effusions of breast cancer patients, 5) ascites 
fluids from ovarian cancer patients, and 6) liver metastasis of breast cancer and pancreatic 
cancer of neuroendocrine origin. The majority of cells cultured with this protocol maintained 
the epithelial phenotype and could be cultured for ~10 −12 passages and provided >5 
million cells for cryopreservation, functional studies and/or to immortalize/transform in case 
of primary non-transformed cells. Non-epithelial cells could be easily separated from 
epithelial cells by flow cytometry and cultured for further evaluation of the 
microenvironment. In addition, tumor cells formed tumors in NSG mice thus allowing 
simultaneous characterization of patient-derived primary and metastatic tumor cells both in 
vitro and in vivo.
Materials and Methods
Creating and propagating primary cells
Fresh or cryopreserved, de-identified tissues samples were obtained from the Indiana 
University (IU) Simon Cancer Center Tissue Bank or Komen Tissue Bank (KTB) at IU 
School of Medicine, Indianapolis, after informed consent from the donors. All experiments 
were carried out in accordance with the approved guidelines of the Indiana University 
Institutional Review Board. The 804G cells were a generous gift from Dr. Rajagopal 
(Harvard Medical School). The 804G cells were grown in RPMI media (10–0400CV, 
Corning) with 10% FBS and 1% penicillin and streptomycin. Conditioned medium (CM) 
from the 804G cells was harvested once the cells were confluent. No more than 2–3 batches 
of CM were collected from one culture. The CM was filtered through 22-μm filters, divided 
into aliquots in 50 ml tubes and frozen at −20°C for future use. A day before the tissues 
were processed, 60 mm culture dishes were prepared by adding 5 ml of the thawed 804G 
CM followed by overnight incubation at 37°C. Just prior to use, the CM was aspirated and 
the dish was washed with PBS once. This CM is enriched for laminin-related components 
(9).
Table S1 provides details of tissues used in this study. Solid tissues dissociation protocol 
along with primary cell culture media has been described previously (7). The primary cell 
media was supplemented with 1 μM of BMP inhibitor DMH-1 (#4126, Tocris), 1 μM of 
TGFβ inhibitor A-83–01 (#2939, Tocris), 5 μM of ROCK inhibitor Y-27632, and 4 μl/ml of 
adenine (6 mg/ml stock, A9001, Sigma-Aldrich). Pleural effusion or ascites fluids were 
centrifuged at 1000 RPM for five minutes to collect cell pellet and the pellet was washed 
twice in PBS before platting on 804G CM coated plates. Medium was changed the next day 
to remove cellular debris and floating cells. The cells could be cultured for 10–12 passages 
using this method.
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Adherent cells were collected by trypsinization, stained using antibodies CD49f-APC 
(FAB13501A), CD140b-FITC (FAB1263F) (R&D Systems), PROCR (CD201)-PE 
(130-105-256), EpCAM-PE (130-091-253), EpCAM-APC (130-091-254) (Miltenyi Biotech 
Inc.), CD271-APC (345108) (Biolegend), CD44-APC (559942), CD24-PE (555428), CD73-
PE (561014), CD90-APC (559869), CD166-PE (559263), JAM-1-PE (552556), MUC-1-
FITC (559774) (BD Pharmingen), CD10-PE (340920) (BD Biosciences), and CD117-FITC 
(11-1178-42) (eBioscience), and were acquired using a BD LSR II flow cytometer. Data 
were analyzed using CellQuest or FlowJo software. Forward and side scatter were used to 
ensure that only live cells were considered in the analysis. Gating was done using 
appropriate FITC (555573), PE (555749) and APC (555576) (BD Pharmingen) isotype 
control antibodies and only a representative isotype control for two fluorescent markers are 
shown.
Mammosphere formation assay
Mammosphere assay in 6-well plate at a density of 5000 cells/mL has been described 
previously (10). Phase contrast images were taken at day 5. Mammospheres were collected, 
washed, and trypsinized to obtain single-cell suspensions. Cells were stained with indicated 
antibodies and subjected to flow cytometry.
Determination of in vitro growth of primary cells
We used the KTB200, KTB201, and KTB202 primary cells to characterize the growth 
kinetics and in vitro survival of primary cells in culture. Growth kinetics was evaluated from 
successive cell counts. 2.5 × 105 cells per cell type were seeded on 60-mm dishes at day zero 
and incubated under standard conditions. Cells were harvested every two days by 
trypsinization, counted using a hemocytometer, and 2.5 × 105 cells were reseeded for the 
next culture.
Culturing and characterization of cells in 3D collagen or matrigel scaffolds
Floating collagen scaffold was prepared based on a protocol from Linnermann et al., with 
some modifications as detailed in Kumar et al. (2,11). Matrigel basement membrane 
(354234, Corning) was slowly thawed on ice. 8-chambered cover-glass system (155409, 
Lab-Tek II) was coated with 40 μl of matrigel per well and spread evenly to cover the 
bottom surface. The chamber was incubated for 30 minutes at 37 °C for the gel to solidify. 
400 ul of overlay media comprising primary cell media as described above with 2% matrigel 
and 6000 cells per well were added. The medium was changed every 3–4 days and the cells 
were cultured to 10 to 12 days. Immunofluorescence staining of 3D structures has been 
described previously (2).
RNA isolation and quantitative RT-PCR
Total RNA was isolated using RNeasy Kit from Qiagen and 1 μg of RNA was used to 
synthesize cDNA with Bio-RAD iScript cDNA Synthesis Kit. Quantitative RT-PCR (qRT-
PCR) was performed using Taqman universal PCR mix and predesigned Taqman assay 
primers with best coverage from Applied Biosystems. The following assays were used in our 
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study: ACTB (Hs01060665_g1), ESR1 (Hs01046816_m1), GATA3 (Hs00231122_m1) 
FOXA1 (Hs04187555_m1) and FOXC1 (Hs00559473_s1). Applied Biosystems 
StepOneplus real time PCR system was used for PCR and fluorescence detection and the 
StepOne software was used for analysis.
Immunofluorescence staining of monolayer culture
Cells were cultured in glass bottomed microwell dish (P35G-0–14-C, MatTek Corporation) 
and stained with KRT14 (ab7800, Abcam), KRT19 (ab52625, Abcam), and KRT17 
(ab53707, Abcam) primary antibody according to protocol described previously (2). Cells 
were stored in PBS in dark and images were taken within 48 hours of staining with Olympus 
FV1000 MPE inverted confocal microscope.
Xenograft studies
The Indiana University Animal Care and Use Committee approved the use of animals in this 
study and all procedures were performed as per NIH guidelines. Primary cells created from 
pleural effusions of breast cancer or TNBCs (5×105 cells) with 50% Basement Membrane 
Matrix (BME) Type 3 (100 μl volume) were implanted into the mammary fat pad of 5–6 
week old female NSG (NOD/SCID/IL2Rgnull) mice. A 60-day slow release estradiol (0.72 
mg) was implanted at the time of mammary fat pad injection, irrespective of the injected 
breast cancer subtype. Tumor growth was measured weekly and tumor volume was 
calculated as described previously (12). After 2–5 months, lungs and primary tumors were 
collected and processed for hematoxylin and eosin (H&E), ERα, PR, GATA3, and FOXA1 
staining.
Immunohistochemistry
H&E, ERα, PR, GATA3, and FOXA1 immunostaining was performed at the CLIA certified 
Indiana University Health Pathology Laboratory and the whole slide digital imaging system 
of Aperio (ScanScope CS) was used for imaging. The following antibodies were used: ER 
(clone EP1, Dako IR 084), PR (#RB-9017-P, NeoMarkers), FOXA1 (Santa Cruz sc-6553), 
and GATA3 (Santa Cruz sc-268).
Statistical analysis
Statistical analyses were performed using GraphPad Prism software program (version 6.0). P 
values below 0.05 were considered statistically significant.
Results
We have developed a method for propagating the primary cells from normal, cancerous, and 
metastatic tissue samples with appropriate modifications to growth media. Cells propagated 
from more than 30 primary breast tissues (>6 healthy donors, two BRCA1-mutants, three 
BRCA2-mutants with one right and left breasts of the same donor, three PALB2 high-risk, 
two protective alleles, tumors with adjacent normal tissues from the same patients, several 
triple-negative breast cancers (TNBC), three breast cancer pleural effusion fluids, four breast 
cancer metastasis from different organs, one liver metastasis of pancreatic cancer-
neuroendocrine subtype, and three ascites fluids of ovarian cancer patients) were analyzed 
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(Table S1). These extensive analyses recognized enormous phenotypic heterogeneity in the 
normal breast and tumors.
Normal breast contains multiple subpopulations of cells
We subjected primary breast cells to phenotypic analyses using established and recently 
discovered markers that define the normal and cancer stem cells (CSCs), pluripotent somatic 
stem cells, progenitor, differentiated, luminal, basal/myoepithelial cells, and ERα-positive 
subpopulation of cells (2,13,14). Similar to results obtained with cells propagated using the 
previous epithelial reprogramming assay (7), this new culturing method enabled us to 
document enormous phenotypic heterogeneity in the normal breast. The expanded cell 
populations are described as CD49f+/EpCAM- stem/basal-enriched cells, CD49f+/EpCAM+ 
luminal progenitor cells, CD49f-/EpCAM+ mature luminal cells, CD44+/CD24- stem/basal 
cells, CD44+/CD24+ stem/luminal progenitor cells, CD44-/CD24+ differentiated cells, 
CD201+/EpCAM- multi-potent stem cells, CD271+ rare basal cells in luminal breast cancer 
(relevant in anti-estrogen resistance models), CD73+/EpCAM+/CD90- rare endogenous 
pluripotent somatic stem cells, CD73+/CD90+/EpCAM- potential mesenchymal stem cells, 
CD10+/EpCAM- basal/myoepithelial cells, ALCAM (CD166)+ cells that are enriched for 
ERα, and JAM-A+ cells, which are enriched for cancer stem cell phenotype (15–17). Flow 
cytometry characterization of breast epithelial cells from six healthy women (KTB200–205) 
showed remarkable variability in stem/basal, progenitor and mature/differentiated cell 
subpopulations (Figure 1A and Figure S1). All samples were from pre-menopausal women 
(20–55 age range, 23–41 BMI range, Table S1). Using a combination of CD44 and EpCAM, 
we were able to document the presence of luminal (CD44-/EpCAM+ or CD44low/EpCAM+) 
and basal (CD44+/EpCAMlow) cells (18). Proportion of cells that express the cell adhesion 
molecule MUC1 also varied between samples (Figure S1). MUC1 is expressed 
predominantly in CD24+ luminal cells and these cells often display higher self-renewal 
capacity and are metastatic (19,20). With respect to rare pluripotent somatic stem cells (13), 
our technique expanded this population, as a significant portion of CD73+/CD90- cells was 
EpCAM+ (Figure 1B). Cells propagated using this assay are free of fibroblasts as they 
lacked the expression of CD140b, which identify fibroblasts (21) (Figure S1). We also did 
not find cells expressing CD117, a putative marker of luminal progenitor cells (22) (Figure 
S1). These results suggest inter-individual heterogeneity among the normal breasts, 
particularly in number of breast epithelial cells expressing markers that identify cells as 
stem, basal or luminal cells, similar to our previous report (7). However, as we indicated in 
our previous report, because of limited sample size, the observed heterogeneity cannot be 
attributed to differences in age, BMI or time of sample collection (luteal or follicular phase).
We performed serial dilution cell proliferation assay to determine the number of passages 
these cells can be maintained. Proliferation kinetics varied from samples to samples and 
declined by around passage 7 (Figure S1). However, by the time cells reached passage 7, 
couple of million cells could be easily obtained for immortalization and functional studies.
Breast epithelial cells from women carrying high-risk mutations:
To evaluate the suitability of the assay for growing cells from high-risk women, we created 
primary cells from prophylactic mastectomy or biopsies of women carrying germline 
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mutations in BRCA1 (two cases), BRCA2 (three cases, one with tissues from both breasts) 
or PALB2 (three cases). Staining with multiple antibody combinations did not show any 
patterns that are distinct from the cells cultured from healthy breasts (Figure 2A and Figure 
S2). It is also remarkable that inter-individual differences in staining patterns were noted 
among high-risk patients analyzed in the study (Figure S2). For example, CD271/EpCAM, 
CD10/EpCAM and MUC1/EpCAM staining patterns of two BRCA2 mutants and three 
PALB2 mutants were different (Figure S2). Thus, it is unlikely that the breasts of high-risk 
women contain phenotypically distinct population of cells compared to breasts of healthy 
women. In general, growing epithelial cells from women with PALB2 and CHEK2 
mutations was more difficult than others because of outgrowth of cells with fibroblastic 
appearance or epithelial cells undergoing rapid epithelial to mesenchymal transition (EMT).
Cells with BRCA1 mutations, similar to cells from healthy women, formed acini on collagen 
gel and these acinis were composed of KRT5/6 and KRT17+ cells (Figure S3). We 
compared the staining pattern of cells from both the breasts of a BRCA2 carrier to ensure 
that observed staining pattern is not due to collection of biopsy from specific regions of the 
breast. Randomly collected breast tissues from both the breasts showed similar cell surface 
marker profiles (Figure 2B and Figure S3). Immunofluorescence with basal cell marker 
KRT14 and luminal cell marker KRT19 showed that the majority of cells from high-risk 
women are hybrid cells that expressed both KRT14 and KRT19 (Figure 2C), which is a 
suggested characteristic of cells with luminal progenitor phenotype (23).
We had previously demonstrated that immortalized cell lines derived from healthy breast 
self-renew as well as undergo differentiation when cultured under mammosphere growth 
conditions (2). To determine whether cells from high-risk women differ in their capacity to 
undergo self-renewal and differentiation, we subjected cells from BRCA1 and BRCA2 
carriers to mammosphere assay followed by flow cytometry (Figure 2D and E). Phase 
contrast images of these mammospheres showed similarity between samples. However, as 
noted previously with cells from healthy breasts (2), inter-individual variability in 
differentiation capacity was noted with cells from high-risk women. For example, the 
proportion of cells with differentiated luminal phenotype (CD49f-/EpCAM+ or CD44-/
EpCAM+ cells) increased under mammosphere condition compared to 2D growth condition 
but the degree of increase varied between samples (Figure 2A and E). Staining patterns of 
mammospheres with additional markers are shown in Figure S3.
Cells grown from women with protective alleles show enhanced differentiation 
capacity: Although epidemiologic and genome-wide association studies have identified 
various risk, predisposition, and protective alleles including new 65 risk loci for breast 
cancer (24,25), functional analyses of these risk loci have been difficult because of limited 
cell resources. To determine whether culture system developed here is useful in this regard, 
we focused on a recently described breast cancer protective variant in Latinas on 
chromosome 6q25 located 5’ of Estrogen Receptor 1 (ESR1) gene, which is limited to 
Indigenous American Ancestry (26). We examined DNA from self-reported 43 Hispanic 
women from whom cryopreserved normal breast tissues were available at the Komen Tissue 
Bank (KTB). Among these women, three carried the protective allele (Figure 3A) but viable 
cells could be generated from two samples. These cells were less proliferative than cells 
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generated from healthy or high-risk women and only limited number of experiments could 
be performed. Cell surface markers profiles showed clear enrichment of cells with 
differentiated/luminal characteristics (Figure 3B and Figure S4A and B). For example, 
unlike in cases of healthy or high-risk women, the majority of cells from women with 
protective alleles were CD49f-/EpCAM+, CD271-/EpCAM+ and CD201-/EpCAM+. In 
addition, these cells had higher proportion of cells that were KRT14-/KRT19+ compared to 
cells from non-carriers of protective alleles or high-risk individuals (Figure 3C), and were 
KRT17+ (Figure S4B). Furthermore, cells from one protective allele carrier, which we were 
able to grow for additional analyses, expressed higher levels of luminal cell markers ESR1, 
FOXA1, and GATA3 compared to cells from normal (KTB51) and high-risk individuals 
(Figure 3D). In mammosphere assays, cells with protective alleles generated very small 
spheres compared to cells generated from two Hispanic women not carrying the protective 
allele (Figure 3E). Thus, the assay established here can be used to characterize cells from 
women carrying distinct risk loci.
Individualizing tumor characterization through propagation of tumor and adjacent normal 
from the same patient.
Since gene expression in normal tissues shows inter-individual variations due to single 
nucleotide polymorphism in the gene regulatory regions (27), we had recently proposed that 
normal cells from the same patient need to be used to determine cancer specific gene 
expression changes (28). Although the use of cells from normal tissues adjacent to tumor is 
far from perfect because of cancer-induced field defects on adjoining cells (29,30), it is still 
better to use those cells or from the unaffected contralateral breast than normal cells from 
unrelated individuals as controls to identify cancer-specific gene expression changes. 
Towards achieving this goal, we established culture conditions to grow tumor and tumor 
adjacent normal from the same patient. Representative flow cytometry profiles with various 
markers are shown in Figure 4A and Figure S4C and D. Both tumor and the adjacent normal 
showed similar marker profiles except that tumors had a minor CD49fhigh/EpCAM+ 
population. Cells derived from not all tumors that were characterized showed similar profiles 
as samples from triple negative breast cancers (TNBCs) showed a distinct profile than the 
sample described above (Figure 4B and Figure S4D). Tumor cells were KRT14+/KRT19+ 
suggesting their luminal progenitor characteristics, similar to flow cytometry stain pattern 
(Figure 4C). We have created a bank of tumor cells from at least 15 patients with few cases 
of paired tumor and tumor adjacent normal, which could be utilized for functional studies.
Tumor cells form ductal and acinar-like structures on collagen gels: Since 
organoid culture system is gaining traction for various types of studies including screening 
for anti-cancer therapies (31), we determined whether tumor cells form organoid-like 
structures in 3D. On matrigel, tumor cells formed spheres, whereas on collagen gels, cells 
formed elongated structures that resembled breast ducts (Figure 5A). Immunofluorescence 
of collagen gel structures with KRT14, KRT17 and KRT19 showed these ducts are KRT17+ 
and are lined by KRT14+/KRT19+ double positive cells (Figure 5B). Most breast cancers 
are believed to originate from luminal progenitor cells, which are typically KRT14+/
KRT19+ (23).
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Breast cancer cells propagated from pleural effusions develop estrogen receptor alpha 
(ERα)-positive tumors in NSG mice.
Although it has proven extremely difficult to cultivate breast epithelial cells that express 
ERα, there have been few recent advances in culture methods that enabled propagation of 
ERα-positive cells (2,14). Similarly, patient-derived tumor xenograft (PDX) models heavily 
favor ERα-negative breast cancers relative to ERα+ PDXs (32). In addition, very rarely, 
tumor cells and PDXs have been created from the same tumors. Since we had >90% success 
rate in generating cells from tumors, we next investigated whether cells derived from breast 
tumors or pleural effusions can create tumors in NSG mice. Detailed characteristics of tumor 
cells derived from pleural effusions developed from two ERα+ tumors are described in 
Figure 6A and Figure S5. Flow cytometry patterns of cells grown from two pleural effusions 
were different with pleural effusion #2 containing higher proportion of EpCAM+ cells. Cells 
from both pleural effusions contained significant levels of ALDEFLUOR+ cancer stem cells 
(33). Western blotting showed expression of ERα in effusion #2, although very low levels of 
ERα were detectable in the effusion #1 (Figure 6B). Cells derived from effusion #2 
generated tumors in the mammary fat pad of NSG mice by two months post-implantation 
(Figure 6C), which expressed all three markers of luminal breast cancer- ERα, FOXA1, and 
GATA3 but lacked progesterone receptor (PR), indicating luminal B characteristics (Figure 
6D). A lung metastatic nodule, which expressed GATA3, was also detected (Figure 6E). We 
have generated tumors from primary TNBC cells, which could be re-implanted into 
additional animals similar to PDX models (Figure 6F). Whole genome sequencing of these 
TNBC cells showed mutation patterns observed in breast tumor samples (data not shown). 
Thus, the method described here provides resources of patient tumor-derived primary cells 
and tumors from these cells for functional studies.
Propagation of cells derived from liver metastasis and from other cancers
Metastasis is the main cause of cancer death and several studies have shown distinct 
differences between primary tumors and metastasis (34,35). We had previously shown that 
epithelial reprogramming assay could be used to grow and perform genomics of liver 
metastasis of various cancers (36). However, because mouse embryonic feeder layer cells 
were needed to grow cancer cells, sorting of cancer cells by flow cytometry was required 
before sequencing, and bioinformatics analyses of genomic data required additional steps to 
ensure that sequence reads are not from residual contaminating mouse DNA. To determine 
whether metastatic cells grown under reprogramming growth conditions can adapt to the 
current method, we transferred cells from a liver metastasis of a breast cancer grown initially 
under reprogramming assay to the new method. Indeed, cells readily adapted to the new 
method and a significant number of cells could be obtained for phenotypic characterization 
(Figure 7A and Figure S5). The majority of cells were CD49f+/EpCAM+, Jam-A+/EpCAM
+ and CD271+/EpCAM+.
We extended this method to propagate cells from other cancer types. Cells from ascites fluid 
of ovarian cancer patients (OV351-MT to OV353-MT) and liver metastasis of pancreatic 
cancer-neuroendocrine subtype were generated and characterized with various cell surface 
markers. Cells from ascites fluid of ovarian cancer patients displayed the phenotypic 
heterogeneity and exhibited predominant CD49f+/EpCAM-, CD44+/CD24-, CD44+/
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EpCAM-, CD73+/CD90+, CD201+/EpCAM-, CD166+/EpCAM, and CD10+/EpCAM- 
phenotypes (Figure 7B and Figure S6). However, it is likely that few of the cell types that do 
not express EpCAM are non-cancer stromal cells. Nonetheless, the method permitted 
propagation of EpCAM+ cells, which can be sorted by flow cytometry for functional 
studies.
The cells from liver metastasis of pancreatic cancer-neuroendocrine subtype contained 
predominantly CD49f+/EpCAM+, CD44+/CD24low, CD44+/EpCAM+, CD73+/CD90-, 
CD201low/EpCAM+, CD271-/EpCAM+, CD10-/EpCAM+, CD166+/EpCAM+, CD117-/
EpCAM+, MUC-1-/EpCAM+, JAM-1+/EpCAM+, and CD140b-/EpCAM+ subpopulations 
(Figure 7C and Figure S6). A fraction of these cells were CXCR4-positive, which is 
expressed only in metastatic cancer stem cells of pancreatic cancer and is required for 
metastasis (37). Taken together, detailed characterization of various cells from different 
sources documents that our propagating method is suitable for growing primary cells, 
establishing heterogeneity of cancer cells in tumors, and provides a replenishable source of 
live primary cells for functional studies.
Discussion
Functional modeling of breast epithelial hierarchy and stromal-epithelial cell interactions 
have been difficult due to inability to obtain sufficient stem-progenitor-mature epithelial 
cells and stromal cells. Establishment of such techniques for modeling of the normal breast 
in vitro is critical if progress made in identifying various risk and protective alleles of 
cancers to have an impact in clinic. Similarly, further advancement is needed to translate 
knowledge gained through single cell sequencing technologies, which are currently 
descriptive cataloguing of different cell types in primary and metastatic tumors without 
allowing functional evaluation of different cell types (35). In this study, we report in vitro 
propagation method for primary cells from different sources including breast, ovary, and 
metastasis. These cells are suitable for “omics” studies as TNBC cells from one of the 
patients have already been sequenced and found to have mutations enriched in breast cancers 
and additional samples are currently being sequenced (data not shown). Most importantly, 
sequence information can be obtained when primary tissue is very limited. We expect these 
tumor-derived cells to be also compatible for proteomics and metabolomics studies with and 
without prior exposure to chemotherapeutics. Other advantages of the method are that it is 
relatively inexpensive, adaptable in any labs and cancer cells can be grown from 
cryopreserved tissues. We have found that cryopreserving tissues with ROCK inhibitor 
yields higher number of live cells (7). Although continuous passage leads to drift in 
proportion of different cell types, the original cell types remain after passage. Samples with 
disproportionately higher number of fibroblast-like cells compared to epithelial-like cells 
within a week of initiating culture, which can be identified through phase contrast 
microscopy, show a higher tendency of drift to non-epithelial (EpCAM-) cells with 
continuous passage. Differential trypsinization (two minutes at room temperature) or flow 
cytometry sorting can be used to enrich epithelial cells in culture. The only caveat of this 
modification is that cancer cells that have undergone EMT would get excluded from 
functional studies.
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Single cell studies are gaining popularity for better understanding of heterogeneity of cell 
types in an adult organ. Fifteen and three epithelial cell types have been described in the 
mouse mammary gland and the human breast, respectively (38,39). Since the assay 
described here allows propagation of cells from a core biopsy and cells form distinct 
structures on a 3D matrix, functional studies of cells from different clusters can now be 
performed with and without addition of stromal cells. Additional advantage of this system is 
the availability of cells that carry breast cancer risk alleles. Depending on the type of risk 
alleles, these cells can be easily immortalized with human telomerase. While we could easily 
immortalize cells with BRCA1or BRCA2 mutations, generating cell lines from PALB2 and 
CHEK2 carriers as well as those with protective alleles has so far proved difficult. 
Phenotypic analyses using ~10 cell surface marker combinations did not reveal unique 
features of cells obtained from high risk individuals, which is bit surprising considering a 
previous study, which demonstrated enrichment of cells with luminal progenitor properties 
in the breast of BRCA1 mutant carriers (17). However, we were able to document enhanced 
differentiation properties of cells obtained from women who carry breast cancer protective 
alleles, which clearly indicates the role of proper differentiation in protecting against breast 
cancer.
We had previously demonstrated that short-term culturing followed by sequencing of 
cultured tumor cells could detect functionally important mutations that are otherwise 
undetectable upon direct sequencing of tumors (36). Culturing for short duration as such did 
not introduce mutations. Culturing method used at that time required propagation of tumor 
cells on a mouse fibroblast feeder layer and purifying tumor cells by flow cytometry before 
sequencing. The new method described here eliminates those requirements. Despite TNBCs 
displaying higher rate of mutations than other breast cancer subtypes (40) and data from 
many samples already available, very few are detected across multiple TNBCs and very 
rarely the impact of these mutations using the same tumor material could be studied. In 
general, cancers believed to contain 2–8 “driver” mutations and 30–60 protein-coding 
changes in passenger genes that alter cellular functions (41). We hope that the assay 
described here would not only enhance detection of additional mutations but also evaluation 
of presumed driver and passenger mutations in future. Furthermore, new mutations detected 
from these cell lines can be incorporated for screening of distant metastasis using ctDNA 
technology (42). In this respect, tumor cells generated from our culturing method form 
unique structures under 3D growth conditions and develop tumors in NSG mice, similar to a 
direct PDX model. Availability of millions of cancer cells from patients would permit 
further refinement of these models including characterizing growth properties of specific 
subclones with or without co-culture with stromal cells, in vitro high throughput drug 
screening on an individual patient basis and further validation of the effective drugs in 
xenograft models. Sufficient cells can be obtained within a month of initiating culture for 
rapid in vitro screening for drug sensitivity. In this respect, a recent study that utilized single 
cell genomics and TNBC samples from patients receiving neoadjuvant therapy concluded 
that drug resistant genotypes are pre-existing in tumors and adaptively selected during 
neoadjuvant therapy (43). Relatively inexpensive way to generate cells from TNBCs 
described here would enable identification and characterization of such pre-existing drug 
resistant clones. While breast cancer research community has placed significant emphasis on 
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finding cure for TNBCs, similar degree of attention is also needed for ERα-positive breast 
cancer because of higher number of patients with this disease type and its late recurrence 
(44). Recent studies have identified set of genes that predict early and late recurrence (45). 
However, developing in vitro models with patient-derived cells to functionally characterize 
genes in the signature has proven to be a challenge. Our assay has overcome this challenge 
as the cultured cells derived from recurrent tumors maintain ERα and one of our future 
goals is to establish cultures from metastasis that carry mutations in ERα, which are 
frequently observed in metastasis but not in primary tumors (46). We do acknowledge that, 
similar to PDX model (47), clonal selection of different tumor cells during culturing is one 
of the limitations of this assay. Nonetheless, simplicity of the assay allows propagation of 
cells from multiple cancers and serves as a resource for validation of pan-cancer genomic 
signatures including DNA methylation and chromatin accessibility identified through 
bioinformatics analyses (48–50).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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CHEK2 checkpoint kinase 2
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C-x-C chemokine receptor type 4
DMSO dimethylsulfoxide
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FBS fetal bovine serum
KRT keratin
KTB Komen tissue bank
MUC1 mucin 1
NSG NOD/SCID/IL2Rgnull
PALB partner and localizer of BRCA
PBS phosphate buffered saline
PDX patient derived xenograft
PR progesterone receptor
ROCK Rho-associated kinase
TGFβ transforming growth factor
TNBC triple negative breast cancer
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Our method expands the scope of individualized studies of patient-derived cells and 
provides resources to model epithelial-stromal interactions under normal and 
pathological conditions.
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Breast epithelial cells from the normal breast contain multiple cell types and show inter-
individual heterogeneity. A) Breast epithelial cells isolated from the normal breasts of five 
clinically healthy women show inter-individual differences in staining patterns with CD49f, 
CD44, CD24, CD90, CD73, and EpCAM antibodies. B) The culturing method enriches for 
rare endogenous pluripotent somatic stem cells based on CD73/CD90/EpCAM staining 
patterns. EpCAM expression was seen in greater than 96% of CD73+/CD90- cells in 
KTB205.
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Breast epithelial cells with luminal progenitor characteristics can be grown from breast 
cancer high-risk carriers. A) Breast epithelial cells from BRCA1, BRCA2, and PALB2 
mutation carriers show variable subpopulation of cells based on CD49f/EpCAM, CD44/
CD24 and CD44/EpCAM staining patterns. B) Breast epithelial cells propagated from 
randomly selected regions from two breasts of a BRCA2 carrier show similar phenotypes 
based on CD49f/EpCAM, CD44/CD24 and CD44/EpCAM staining patterns. C) BRCA1 
and BRCA2 mutant breast epithelial cells are enriched for KRT14+/KRT19+ luminal 
progenitor cells as determined by immunofluorescence. D). BRCA1 and BRCA2 mutant 
cells form mammospheres. E) Cells in mammospheres show different degree of 
differentiation compared to cells grown in 2D culture. For example, CD49f-/EpCAM+ cells, 
which are considered differentiated luminal cells, increased under mammosphere condition 
compared to 2D culture as shown in A.
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Breast epithelial cells propagated from women with breast cancer protective alleles show 
differentiated characteristics. A) Distribution patterns of the breast cancer protective SNP 
rs140068132 in 43 self-reported Hispanic women. B) Breast epithelial cells from women 
with protective alleles show higher number of CD49f-/EpCAM+, CD271-/EpCAM+ and 
CD201-/EpCAM+ differentiated cells. C) Cells with protective alleles are predominantly 
KRT14-/KRT19+ differentiated cells compared to cells from another Hispanic women not 
carrying protective allele (KTB205). KTB205 contained both KRT14+/KRT19+ and 
KRT14-/KRT19+ cells. D) Cells with protective alleles express higher levels of luminal 
genes such as ESR1, FOXA1, and GATA3 compared to non-carriers (KTB51) as well as 
BRCA1 and BRCA2 mutant carriers. mRNA levels measured through qRT-PCR are shown. 
Differences in expression between non-carrier (KTB51) and protective allele carrier 
(KTB251-PA) with all genes are statistically significant (p<0.05, indicated by asterisks). 
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Similarly, differences in expression between high-risk carriers and protective allele carrier 
are also significant. E). Breast epithelial cells from protective carriers generate small 
mammospheres compared to breast epithelial cells from Hispanic women without the 
protective allele.
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Characteristics of cells propagated from tumors and tumor adjacent normal cells. A) ER
+/PR+ tumor cells and tumor adjacent normal cells of the same patient show limited 
heterogeneity. B) Distinct profiles of tumor cells propagated from an ER+/PR- tumor and 
two TNBCs. C) KRT14 and KRT19 staining patterns of ER+/PR- tumor cells. Based on 
merged staining pattern, KRT19 staining appears dominant over KRT14.
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Tumor cells form acinar structures on matrigel and ductal structures on collagen gel. A) 
Phase contrast images of tumor cells on monolayer, matrigel, and collagen gel. B) KRT14, 
KRT17, and KRT19 staining patterns of ductal structures on collagen gel.
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Tumorigenic properties of tumor cells. A) Flow cytometry staining patterns of cells 
propagated from pleural effusions of patients who had ER+ breast cancer. B) ERα 
expression pattern in MCF7 cells (positive control), and cells from tumor adjacent-normal 
(N), tumor (T), KTB normal (H) and two pleural effusions. C) Growth characteristics of 
tumors developed in the mammary fat pad of NSG mice injected with cells from pleural 
effusion 2 (PL-02). D) H&E staining and luminal marker expression patterns in PL-02. E) 
PL-02 -derived tumor metastasized to lungs (red arrow), which expressed GATA3. F) 
Growth characteristics of tumors derived from TNBC cells.
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Characterization of cells propagated from sites of metastasis of different cancers. A) Flow 
cytometry profiles of liver metastasis of a breast cancer. B) Flow cytometry profiles of cells 
propagated from ascites fluids of three patients with ovarian cancer. C) Flow cytometry 
profiles of liver metastasis of a pancreatic cancer (neuroendocrine).
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